Clinical Trial Update: TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC [Phase 1]

View source ↗

Summary

Phase 1 study evaluating TGF-beta resistant cytotoxic T-lymphocytes for Epstein-Barr virus–positive nasopharyngeal carcinoma. The trial is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• TGF-beta resistant cytotoxic T-lymphocytes

Snippet

Sponsor: Baylor College of Medicine | Conditions: EBV-positive Nasopharyngeal Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING